RWJBarnabas Health - Newark Beth Israel Medical Center
RWJBarnabas Health - Newark Beth Israel Medical Center
Newark, New Jersey, United States7 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE) | Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, esophageal disorder, neoplasm | Recruiting | Phase 2 | 2026-09-23 | NCT05332002 | |
| ATATcH Alternating Treatment Plans for Advanced Cancer | Head and Neck Neoplasms, Neoplasms by Site, Thoracic Neoplasms, head and neck cancer, lung cancer, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 2 | 2026-04-30 | NCT05358548 | |
| Optimize Neoadjuvant Therapy in HER2-Positive Early-Stage Breast Cancer | HER2-positive Early-stage Breast Cancer | Recruiting | Phase 2 | 2026-04-23 | NCT07402473 | |
| Radiation Therapy Boost Before Surgery for the Treatment of Non-metastatic Breast Cancer | Neoplasms by Histologic Type, Neoplasms by Site, Skin and Connective Tissue Diseases, breast carcinoma in situ, breast disorder, breast neoplasm, carcinoma, epithelial neoplasm, in situ carcinoma, invasive breast carcinoma, neoplasm, skin disorder | Active, not recruiting | Not applicable | 2026-01-22 | NCT04871516 | |
| Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer | Body Weight, Body Weight Changes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Weight Loss, hormone receptor-positive breast cancer | Recruiting | Phase 2 | 2026-01-21 | NCT06518837 | |
| OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple-negative Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Active, not recruiting | Phase 2 | 2025-11-14 | NCT05949021 | |
| Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted | Cardiotoxicity, Chemically-Induced Disorders, Drug-Related Side Effects and Adverse Reactions, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, cardiovascular disorder, heart disorder, injury, neoplasm, radiation injury, skin disorder | Recruiting | Phase 2 | 2025-11-14 | NCT05559164 |